Anaptysbio, Inc (ANAB)
- Sector
- Biotechnology
- Last price
- $45.61
- As of
Kresmion compiles this page from ANAB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ANAPTYSBIO, INC (ANAB): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-12.
See the full ANAB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANAB on one page. Preview it with sample data, then open it live with a free account.
Preview the ANAB dossierActive events for ANAB
- lowEarnings above estimates
Q2-2026: EPS $5.11 vs $0.0031 estimate, +5.11 on a near-zero consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 65% of ANAB (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 72% of ANAB (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1197% to ANAB (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 97% of ANAB (2026Q2)
FREE, NO ACCOUNT
Every event on ANAB, as it fires
You are seeing 5 of 9 events recorded on ANAB since 2026-06-18.
The five above landed across 2 days. The other 4 were recorded on 2 other days. 7 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, ANAB
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on ANAB
ANAB against its peers
ANAB's operating margin of 20.4% ranks in the 88th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ANAB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 235M USD | 16.1M USD | 71 | 11 |
| Gross margin | n/a | 92.3% | n/a | 5 |
| Operating margin | 20.4% | -651.7% | 88 | 11 |
| Net margin | -5.6% | -609.9% | 79 | 11 |
| Return on equity | -35.6% | -45.2% | 68 | 16 |
| 1 year | 84.9% | 1.7% | 81 | 17 |
Peers (19): KRSA, NVAX, NTLA, MLYS, LBRX, DMRA, URGN, IMCR, TSHA, TYRA, RAPP, GHRS, INBX, ABSI, SLS, QURE, PGEN, MNKD, FBRX.D. Left out: KALV.D (no annual filing), KARD (no annual filing), ADRX (no annual filing), AVLN (no annual filing), AAPG (period gap), LYCA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ANAB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ANAB on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ANAB in the last 180 days.
Upstream: SEC EDGAR filings for ANAB
Kresmion, "ANAPTYSBIO, INC (ANAB) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/ANAB. Upstream data: SEC EDGAR filings for ANAB.
Link to this data (HTML):
<a href="https://kresmion.com/research/ANAB">ANAPTYSBIO, INC (ANAB) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ANAB on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ANAB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.